Frank Rimerman Advisors LLC Buys 472 Shares of Hologic, Inc. (NASDAQ:HOLX)

Frank Rimerman Advisors LLC increased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 9.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,427 shares of the medical equipment provider’s stock after buying an additional 472 shares during the period. Frank Rimerman Advisors LLC’s holdings in Hologic were worth $391,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. General Partner Inc. bought a new stake in shares of Hologic during the fourth quarter worth approximately $26,000. Venturi Wealth Management LLC raised its stake in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 261 shares during the last quarter. First Horizon Advisors Inc. raised its stake in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 260 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its stake in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 159 shares during the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Stock Performance

HOLX opened at $60.71 on Monday. The business’s 50-day moving average price is $67.18 and its two-hundred day moving average price is $74.64. Hologic, Inc. has a 1 year low of $60.33 and a 1 year high of $84.67. The company has a market capitalization of $13.62 billion, a price-to-earnings ratio of 19.15, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Leerink Partners downgraded shares of Hologic from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. Citigroup decreased their price objective on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Needham & Company LLC cut shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective for the company. in a report on Monday, February 3rd. Evercore ISI decreased their price objective on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a report on Thursday, February 6th. Finally, Royal Bank of Canada decreased their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Hologic presently has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.